Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – A novel VEGFR inhibitor, tivozanib, improves progression-free survival significantly in patients with metastatic renal cell carcinoma but does not improve overall survival, according…
NEW YORK (Reuters Health) – After primary surgery for early-stage endometrial cancer, adjuvant external beam radiation therapy confers no survival benefit overall, according to a Norwegian study. In…
NEW YORK (Reuters Health) – Among several different DNA-based quantitative polymerase chain reaction (qPCR) assays for detecting a critical JAK2 mutation in myeloproliferative neoplasms, one stands out as…
NEW YORK (Reuters Health) – There’s no evidence that starting treatment with the anti-obesity drug orlistat raises the likelihood of developing colorectal cancer, at least in the short…
By Anne Harding NEW YORK (Reuters Health) – Pediatric inflammatory bowel disease (IBD) patients are not at increased mortality risk compared with their IBD-free peers, but they do…
NEW YORK (Reuters Health) – The identification of differing patterns of oncogenic mutations in squamous cell carcinoma and adenocarcinoma of the cervix may lead to more targeted treatments,…
NEW YORK (Reuters Health) – The psychostimulant modafinil is no better than a placebo in improving fatigue, depression and cognitive function in patients with primary brain tumors (PBT),…
NEW YORK (Reuters Health) – The addition of bevacizumab to adjuvant chemotherapy does not improve invasive disease-free rates in women after resection of breast cancer that’s negative for…
By Will Boggs, MD NEW YORK (Reuters Health) – Patients with unresectable primary spinal sarcoma may benefit from carbon ion radiotherapy (CIRT), Japanese researchers say. Compared with proton…
NEW YORK (Reuters Health) – Bevacizumab appears to be most effective for metastatic colorectal cancer when the primary tumor originates distally, according to a Danish study. However, the…
